E
Marker Therapeutics, Inc.
MRKR
$1.20
$0.065.26%
E
Sell
3/27/2025Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 3/27/2025 due to a noticeable decline in the total return index and volatility index.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 3/27/2025 due to a noticeable decline in the total return index and volatility index.
D
Sell
1/6/2025Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 1/6/2025 due to an increase in the total return index, valuation index and volatility index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 1/6/2025 due to an increase in the total return index, valuation index and volatility index.
E
Sell
12/20/2024Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 12/20/2024 due to a large decline in the total return index, solvency index and valuation index. The quick ratio declined from 5.22 to 2.82.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 12/20/2024 due to a large decline in the total return index, solvency index and valuation index. The quick ratio declined from 5.22 to 2.82.
D
Sell
7/25/2024Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 7/25/2024 due to an increase in the total return index and volatility index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 7/25/2024 due to an increase in the total return index and volatility index.
E
Sell
7/10/2024Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 7/10/2024 due to a decline in the valuation index and total return index.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 7/10/2024 due to a decline in the valuation index and total return index.
D
Sell
6/25/2024Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 6/25/2024 due to an increase in the volatility index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 6/25/2024 due to an increase in the volatility index.
E
Sell
6/10/2024Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 6/10/2024 due to a large decline in the growth index, volatility index and valuation index. Operating cash flow declined 62.07% from -$2.37M to -$3.84M.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 6/10/2024 due to a large decline in the growth index, volatility index and valuation index. Operating cash flow declined 62.07% from -$2.37M to -$3.84M.
D
Sell
6/4/2024Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index and total return index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 6/4/2024 due to an increase in the volatility index and total return index.
E
Sell
5/17/2024Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index and growth index.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 5/17/2024 due to a decline in the volatility index and growth index.
D
Sell
4/29/2024Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 4/29/2024 due to an increase in the volatility index.
E
Sell
4/12/2024Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 4/12/2024 due to a decline in the valuation index and volatility index.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 4/12/2024 due to a decline in the valuation index and volatility index.
D
Sell
7/10/2023Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 7/10/2023 due to an increase in the volatility index and total return index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 7/10/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D on 03/14/2023.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 1.96 to 1.75.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 1.96 to 1.75.
D
Sell
8/4/2022Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 8/4/2022 due to an increase in the volatility index.
D
Sell
7/20/2022Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index.
D
Sell
6/29/2022Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 6/29/2022 due to an increase in the volatility index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 6/29/2022 due to an increase in the volatility index.
D
Sell
6/13/2022Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 6/13/2022 due to a decline in the volatility index.
D
Sell
5/16/2022Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 5/16/2022 due to an increase in the growth index. Earnings per share increased from -$0.1198 to -$0.1192.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 5/16/2022 due to an increase in the growth index. Earnings per share increased from -$0.1198 to -$0.1192.
D
Sell
5/5/2022Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 5/5/2022 due to an increase in the growth index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 5/5/2022 due to an increase in the growth index.
E
Sell
4/20/2022Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
Marker Therapeutics, Inc. (MRKR) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index.
D
Sell
4/19/2022Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 4/19/2022 due to a decline in the volatility index and total return index.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 4/19/2022 due to a decline in the volatility index and total return index.
D
Sell
3/22/2022Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 3/22/2022 due to a noticeable increase in the growth index, solvency index and valuation index. Operating cash flow increased 25.44% from -$6.52M to -$4.86M, earnings per share increased from -$0.1496 to -$0.1198, and EBIT increased 2.59% from -$10.02M to -$9.76M.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 3/22/2022 due to a noticeable increase in the growth index, solvency index and valuation index. Operating cash flow increased 25.44% from -$6.52M to -$4.86M, earnings per share increased from -$0.1496 to -$0.1198, and EBIT increased 2.59% from -$10.02M to -$9.76M.
D
Sell
12/1/2021Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 12/1/2021 due to a decline in the total return index and volatility index.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 12/1/2021 due to a decline in the total return index and volatility index.
D
Sell
11/15/2021Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 11/15/2021.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 11/15/2021.
D
Sell
11/8/2021Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
4/27/2021Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 4/27/2021 due to an increase in the total return index and valuation index.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 4/27/2021 due to an increase in the total return index and valuation index.
D
Sell
3/11/2021Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 3/11/2021 due to a major decline in the solvency index, growth index and valuation index. Operating cash flow declined 46.69% from -$4.24M to -$6.22M, the quick ratio declined from 4.64 to 3.49, and EBIT declined 15.35% from -$7.38M to -$8.51M.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 3/11/2021 due to a major decline in the solvency index, growth index and valuation index. Operating cash flow declined 46.69% from -$4.24M to -$6.22M, the quick ratio declined from 4.64 to 3.49, and EBIT declined 15.35% from -$7.38M to -$8.51M.
D
Sell
5/20/2020Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 5/20/2020 due to an increase in the growth index and volatility index. Operating cash flow increased 10.13% from -$4.56M to -$4.1M.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 5/20/2020 due to an increase in the growth index and volatility index. Operating cash flow increased 10.13% from -$4.56M to -$4.1M.
D
Sell
5/1/2020Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, total return index and volatility index.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 5/1/2020 due to a significant decline in the efficiency index, total return index and volatility index.
D
Sell
3/16/2020Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 3/16/2020 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 15.24 to 22.06, operating cash flow increased 19.47% from -$5.66M to -$4.56M, and earnings per share increased from -$0.1196 to -$0.1111.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 3/16/2020 due to a significant increase in the efficiency index, growth index and solvency index. The quick ratio increased from 15.24 to 22.06, operating cash flow increased 19.47% from -$5.66M to -$4.56M, and earnings per share increased from -$0.1196 to -$0.1111.
D
Sell
12/18/2019Downgrade
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 12/18/2019 due to a large decline in the growth index, total return index and efficiency index. Operating cash flow declined 35.52% from -$4.18M to -$5.66M, and total capital declined 6.87% from $51.98M to $48.41M.
Marker Therapeutics, Inc. (MRKR) was downgraded to D- from D on 12/18/2019 due to a large decline in the growth index, total return index and efficiency index. Operating cash flow declined 35.52% from -$4.18M to -$5.66M, and total capital declined 6.87% from $51.98M to $48.41M.
D
Sell
11/14/2018Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 11/14/2018 due to a large increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.4065 to -$0.3195, net income increased 8.82% from -$4.81M to -$4.39M, and EBIT increased 5.25% from -$4.67M to -$4.43M.
Marker Therapeutics, Inc. (MRKR) was upgraded to D from D- on 11/14/2018 due to a large increase in the growth index, efficiency index and volatility index. Earnings per share increased from -$0.4065 to -$0.3195, net income increased 8.82% from -$4.81M to -$4.39M, and EBIT increased 5.25% from -$4.67M to -$4.43M.
D
Sell
8/14/2018Downgrade
TapImmune, Inc. (TPIV) was downgraded to D- from D on 8/14/2018 due to a decline in the growth index. EBIT declined 46.17% from -$3.2M to -$4.67M, earnings per share declined from -$0.3009 to -$0.4065, and operating cash flow declined 2.25% from -$2.35M to -$2.4M.
TapImmune, Inc. (TPIV) was downgraded to D- from D on 8/14/2018 due to a decline in the growth index. EBIT declined 46.17% from -$3.2M to -$4.67M, earnings per share declined from -$0.3009 to -$0.4065, and operating cash flow declined 2.25% from -$2.35M to -$2.4M.
D
Sell
5/30/2018Upgraded
TapImmune, Inc. (TPIV) was upgraded to D from D- on 5/30/2018 due to an increase in the volatility index.
TapImmune, Inc. (TPIV) was upgraded to D from D- on 5/30/2018 due to an increase in the volatility index.
D
Sell
5/16/2018Upgraded
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 05/16/2018.
Marker Therapeutics, Inc. (MRKR) was upgraded to D- from E+ on 05/16/2018.
E
Sell
4/16/2018Downgrade
TapImmune, Inc. (TPIV) was downgraded to E+ from D- on 4/16/2018 due to a decline in the solvency index, valuation index and efficiency index. Total capital declined 38.34% from $5.94M to $3.66M, and the quick ratio declined from 4.3 to 3.37.
TapImmune, Inc. (TPIV) was downgraded to E+ from D- on 4/16/2018 due to a decline in the solvency index, valuation index and efficiency index. Total capital declined 38.34% from $5.94M to $3.66M, and the quick ratio declined from 4.3 to 3.37.
D
Sell
12/4/2017Upgraded
TapImmune, Inc. (TPIV) was upgraded to D- from E+ on 12/4/2017 due to an increase in the volatility index and total return index.
TapImmune, Inc. (TPIV) was upgraded to D- from E+ on 12/4/2017 due to an increase in the volatility index and total return index.
E
Sell
11/16/2017Downgrade
TapImmune, Inc. (TPIV) was downgraded to E+ from D- on 11/16/2017 due to a decline in the valuation index, total return index and solvency index. The quick ratio declined from 6.32 to 4.3.
TapImmune, Inc. (TPIV) was downgraded to E+ from D- on 11/16/2017 due to a decline in the valuation index, total return index and solvency index. The quick ratio declined from 6.32 to 4.3.
D
Sell
8/8/2017Downgrade
TapImmune, Inc. (TPIV) was downgraded to D- from D on 8/8/2017 due to a significant decline in the efficiency index, volatility index and valuation index.
TapImmune, Inc. (TPIV) was downgraded to D- from D on 8/8/2017 due to a significant decline in the efficiency index, volatility index and valuation index.
D
Sell
7/20/2016Downgrade
TapImmune, Inc. (TPIV) was downgraded to D from D+ on 7/20/2016 due to a major decline in the total return index.
TapImmune, Inc. (TPIV) was downgraded to D from D+ on 7/20/2016 due to a major decline in the total return index.
D
Sell
6/3/2016Upgraded
TapImmune, Inc. (TPIV) was upgraded to D+ from D on 6/3/2016 due to an increase in the volatility index.
TapImmune, Inc. (TPIV) was upgraded to D+ from D on 6/3/2016 due to an increase in the volatility index.
D
Sell
5/18/2016Downgrade
TapImmune, Inc. (TPIV) was downgraded to D from D+ on 5/18/2016 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0275 to -$0.07, and the quick ratio declined from 0.23 to 0.18.
TapImmune, Inc. (TPIV) was downgraded to D from D+ on 5/18/2016 due to a noticeable decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0275 to -$0.07, and the quick ratio declined from 0.23 to 0.18.
D
Sell
4/15/2016Downgrade
TapImmune, Inc. (TPIV) was downgraded to D+ from C- on 4/15/2016 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.03 to -$0.2614, and EBIT declined 29.74% from -$1.74M to -$2.25M.
TapImmune, Inc. (TPIV) was downgraded to D+ from C- on 4/15/2016 due to a noticeable decline in the growth index, volatility index and total return index. Earnings per share declined from $0.03 to -$0.2614, and EBIT declined 29.74% from -$1.74M to -$2.25M.
C
Hold
3/11/2016Downgrade
TapImmune, Inc. (TPIV) was downgraded to C- from C on 3/11/2016 due to a significant decline in the volatility index.
TapImmune, Inc. (TPIV) was downgraded to C- from C on 3/11/2016 due to a significant decline in the volatility index.
C
Hold
12/2/2015Upgraded
TapImmune, Inc. (TPIV) was upgraded to C from C- on 12/2/2015 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 0.24 to 0.69, operating cash flow increased 104.72% from -$813.2 to -$1.66M, and EBIT increased 52.72% from -$1.14M to -$1.74M.
TapImmune, Inc. (TPIV) was upgraded to C from C- on 12/2/2015 due to a noticeable increase in the growth index, volatility index and solvency index. The quick ratio increased from 0.24 to 0.69, operating cash flow increased 104.72% from -$813.2 to -$1.66M, and EBIT increased 52.72% from -$1.14M to -$1.74M.
C
Hold
10/6/2015Downgrade
TapImmune, Inc. (TPIV) was downgraded to C- from C on 10/6/2015 due to a significant decline in the volatility index.
TapImmune, Inc. (TPIV) was downgraded to C- from C on 10/6/2015 due to a significant decline in the volatility index.
C
Hold
9/21/2015Upgraded
TapImmune, Inc. (TPIV) was upgraded to C from C- on 9/21/2015 due to a major increase in the volatility index.
TapImmune, Inc. (TPIV) was upgraded to C from C- on 9/21/2015 due to a major increase in the volatility index.
C
Hold
9/4/2015Downgrade
TapImmune, Inc. (TPIV) was downgraded to C- from C on 9/4/2015 due to a major decline in the volatility index.
TapImmune, Inc. (TPIV) was downgraded to C- from C on 9/4/2015 due to a major decline in the volatility index.
C
Hold
8/14/2015Upgraded
TapImmune, Inc. (TPIV) was upgraded to C from C- on 8/14/2015 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0356 to -$0.5502, and EBIT increased 10.68% from -$1.03M to -$1.14M.
TapImmune, Inc. (TPIV) was upgraded to C from C- on 8/14/2015 due to an increase in the growth index and valuation index. Earnings per share increased from -$0.0356 to -$0.5502, and EBIT increased 10.68% from -$1.03M to -$1.14M.
C
Hold
8/10/2015Downgrade
TapImmune, Inc. (TPIV) was downgraded to C- from C on 8/10/2015 due to a decline in the total return index.
TapImmune, Inc. (TPIV) was downgraded to C- from C on 8/10/2015 due to a decline in the total return index.
C
Hold
6/16/2015Upgraded
TapImmune, Inc. (TPIV) was upgraded to C from C- on 6/16/2015 due to a large increase in the volatility index, total return index and solvency index. The quick ratio increased from 0.11 to 0.44, and debt to equity declined from -0.05 to -0.03.
TapImmune, Inc. (TPIV) was upgraded to C from C- on 6/16/2015 due to a large increase in the volatility index, total return index and solvency index. The quick ratio increased from 0.11 to 0.44, and debt to equity declined from -0.05 to -0.03.
C
Hold
4/16/2015Upgraded
TapImmune, Inc. (TPIV) was upgraded to C- from D+ on 4/16/2015 due to a noticeable increase in the growth index, efficiency index and solvency index. Total capital increased 60.9% from -$603.3 to -$970.7, and debt to equity declined from -0.08 to -0.05.
TapImmune, Inc. (TPIV) was upgraded to C- from D+ on 4/16/2015 due to a noticeable increase in the growth index, efficiency index and solvency index. Total capital increased 60.9% from -$603.3 to -$970.7, and debt to equity declined from -0.08 to -0.05.
D
Sell
11/20/2014Downgrade
TapImmune, Inc. (TPIV) was downgraded to D+ from C- on 11/20/2014 due to a noticeable decline in the growth index, volatility index and efficiency index. Net income declined 308.07% from $753.5 to -$1.57M, earnings per share declined from $0.0485 to -$0.0906, and total capital declined 71.54% from -$2.12M to -$603.3.
TapImmune, Inc. (TPIV) was downgraded to D+ from C- on 11/20/2014 due to a noticeable decline in the growth index, volatility index and efficiency index. Net income declined 308.07% from $753.5 to -$1.57M, earnings per share declined from $0.0485 to -$0.0906, and total capital declined 71.54% from -$2.12M to -$603.3.
C
Hold
5/21/2014Downgrade
TapImmune, Inc. (TPIV) was downgraded to C- from C on 5/21/2014 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 144.48% from -$134.9 to $60.
TapImmune, Inc. (TPIV) was downgraded to C- from C on 5/21/2014 due to a large decline in the growth index, total return index and solvency index. Operating cash flow declined 144.48% from -$134.9 to $60.
C
Hold
2/28/2014Upgraded
TapImmune, Inc. (TPIVD) was upgraded to C from on 2/28/2014 due to a significant increase in efficiency, solvency and stability. Net income increased 10.98% from -$870.8 to -$966.4, total capital increased 10.47% from -$2.23M to -$2.47M, and debt to equity declined from -0.53 to -0.52.
TapImmune, Inc. (TPIVD) was upgraded to C from on 2/28/2014 due to a significant increase in efficiency, solvency and stability. Net income increased 10.98% from -$870.8 to -$966.4, total capital increased 10.47% from -$2.23M to -$2.47M, and debt to equity declined from -0.53 to -0.52.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
